Piramal Pharma Ltd
Pharmaceuticals & Biotechnology | Small Cap
Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio4.00
- Profitability Ratio6.20
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBearish
- 1 WeekNeutral
- 1 MonthNeutral
Piramal Pharma Ltd, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency and growth, with notable increases in operating profit, EPS, asset growth, and net income. Profitability is reasonable, driven by solid returns on capital employed, equity, and assets. However, liquidity appears to be a significant area of concern, and efficiency ratios indicate potential challenges in asset utilization. Financial ratios also reflect some weaknesses, particularly in earnings per share and book value. While coverage ratios are average, the company's growth prospects and profitability offer a positive outlook, but these are counterbalanced by liquidity and efficiency issues. Overall, Piramal Pharma presents a blend of strengths and weaknesses that warrants careful monitoring.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
30.15
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
-64.86
P/B RATIO
2.59
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
2.38
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
24.49
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹158.9 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤28th Apr 26
Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026
UNDEFINED SENTIMENT
Growth ratios suggest strong positive momentum, particularly in operating profit, EPS, asset growth, and net income. However, this is counterbalanced by Revenue growth rate. This indicates strong potential for future expansion and profitability. Strategic investments and market positioning may further enhance growth prospects.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 3.86 | 7.97 | 15.38 | 11.99 | -3.08 |
| Operating Profit Growth Rate | -33.47 | -33.79 | 90.3 | 20.72 | -36.19 |
| Earnings Per Share (EPS) Growth | -109.22 | 430.77 | -455.07 | ||
| Asset Growth Rate | 18.06 | 13.47 | 5.45 | 2.29 | 16.44 |
| Net Income Growth Rate | -54.97 | -149.47 | -109.68 | 405.56 | -458.24 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial ratios reflect mixed performance. While capital expenditures are well-managed, Adjusted EPS, Cash EPS, Book Value Per Share, and DPS indicate areas needing improvement. This suggests potential challenges in earnings quality and shareholder returns. Strategic financial management is essential to optimize these metrics.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 3.24 | -1.56 | 0.12 | 0.67 | -2.2 |
| Cash Earnings Per Share (Cash EPS) | 8.11 | 4.12 | 5.74 | 6.85 | 3.81 |
| Book Value Per Share | 56.47 | 56.77 | 59.8 | 61.37 | 61.51 |
| Dividend Per Share (DPS) | 0 | 0.11 | 0.14 | 0 | |
| Capital Expenditures (CapEx) | 858 | 945 | 710 | 659 | 877 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability ratios indicate a mixed performance. Strong returns on capital employed, equity, and assets are offset by Gross profit margin, Operating margin and Net Margin. Improving these margins would enhance overall profitability. The weighted average calculation underscores the need for a comprehensive approach to profitability management.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.55 | -0.68 | 5.58 | 6.87 | 1.03 |
| Return on Capital Employed (ROCE) | 7 | 2 | 5 | 6 | 3 |
| Return on Equity (ROE) | 5.61 | -2.75 | 0.23 | 1.12 | -3.99 |
| Return on Assets (ROA) | 7.54 | 4.4 | 7.94 | 9.37 | 5.13 |
| Operating Margin | 14.48 | 8.88 | 14.65 | 15.79 | 10.4 |
| Net Margin | 5.73 | -2.63 | 0.22 | 0.99 | -3.68 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency ratios suggest some operational challenges in asset utilization. While days sales in inventory and receivable days are well managed, turnover ratios for fixed assets, inventory, receivables, and capital indicate potential inefficiencies. Optimizing these turnover rates can improve overall performance. The weighted average calculation highlights the need for a balanced approach to asset management.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.95 | 0.95 | 1.02 | 1.13 | 0.99 |
| Inventory Turnover Ratio | 4.73 | 4.64 | 4 | 3.8 | 3.27 |
| Receivables Turnover Ratio | 3.9 | 3.95 | 4.16 | 4.08 | 3.93 |
| Days Sales in Inventory Ratio | 77.17 | 78.66 | 91.25 | 96.05 | 111.62 |
| Receivable Days | 93.59 | 92.41 | 87.74 | 89.46 | 92.88 |
| Capital Turnover Ratio | 0.7 | 0.69 | 0.77 | 0.8 | 0.7 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage ratios suggest an average capacity to meet interest and dividend obligations. While interest coverage is adequate, equity dividend coverage indicates room for improvement. Strengthening these ratios would enhance financial security and investor confidence. The weighted average calculation reflects a moderate ability to handle financial obligations.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.45 | 0.65 | 1.4 | 1.98 | 0.48 |
| Equity Dividend Coverage Ratio | 5.56 | 1.22 | 5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency is strong, indicating a solid long-term financial stability. A high Equity Ratio and low Debt ratios reflect a conservative capital structure, reducing financial risk. This provides a stable foundation for future growth and operational flexibility. This suggests that the company is well-positioned to manage its long-term debt obligations.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.29 | 0.34 | 0.25 | 0.29 | 0.35 |
| Debt to Equity Ratio | 0.41 | 0.52 | 0.33 | 0.41 | 0.54 |
| Equity Ratio | 0.71 | 0.66 | 0.75 | 0.71 | 0.65 |
| Debt To Asset Ratio | 0.22 | 0.25 | 0.17 | 0.22 | 0.25 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position is weak, suggesting potential difficulties in meeting short-term obligations. This could hinder operational flexibility and increase financial risk. While the healthcare industry can have unique working capital dynamics, maintaining adequate liquidity is crucial for managing day-to-day expenses and unexpected needs. The weighted average calculation considers the past five years, highlighting a consistent challenge.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.35 | 1.19 | 1.23 | 1.52 | 1.45 |
| Quick Ratio | 0.91 | 0.77 | 0.75 | 0.94 | 0.88 |
| Cash Ratio | 0.1 | 0.08 | 0.11 | 0.13 | 0.23 |
| Operating Cash Flow Ratio | 0.24 | 0.12 | 0.22 | 0.23 | 0.31 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
| 16 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
Piramal Pharma's management shows a mixed performance. Revenue growth is positive, with a 3-year compounded sales growth of 12% and a TTM growth of 12%. However, profit growth has been inconsistent, with a 3-year compounded profit growth of -38%, despite a high TTM profit growth of 476%. The company's ROCE and ROE are relatively low, indicating capital efficiency issues. Debt management requires attention, as borrowings have increased. While promoter holding is stable, the decrease in FII holding and increase in DII holding may reflect changing investor sentiment. Overall, management has driven sales, but profitability and capital efficiency need improvement.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (3Y CAGR) | 12% | Consistent revenue expansion |
| Sales Growth (TTM) | 12% | Maintained growth momentum | |
| CONS | Profit Growth (3Y CAGR) | -38% | Significant profit decline |
| ROCE | Low | Capital efficiency concerns |
Financial Performance & Growth
Piramal Pharma's revenue is growing, but profit growth is unstable. The 3-year and TTM sales growth are both 12%. The 3-year compounded profit growth is -38%, while the TTM profit growth is 476%. Quarterly results show OPM fluctuations from 1% to 21%, reflecting operational inconsistency. Profit before tax has varied between negative and positive values. Overall, sales have grown, but profits are inconsistent.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 |
| Operating Profit (₹ Cr) | 1,428 | 950 | 629 | 1,197 | 1,445 |
Capital Efficiency & Returns
Piramal Pharma's capital efficiency and returns are weak. ROCE has fluctuated: 7% (Mar 2022), 2% (Mar 2023), 5% (Mar 2024), and 7% (Mar 2025). ROE has been low. The cash conversion cycle increased from 147 days in Mar 2021 to 182 days in Mar 2025, indicating worsening working capital management. These metrics suggest inefficient resource utilization.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE (%) | 7 | 2 | 5 | 7 | |
| Cash Conversion Cycle (Days) | 147 | 153 | 159 | 174 | 182 |
Financial Health & Prudence
Piramal Pharma's financial health is mixed. Borrowings have increased from ₹3,025 Cr in Mar 2021 to ₹4,856 Cr in Mar 2025. Operating profit has fluctuated. The dividend payout was 0% in Mar 2021 and Mar 2023, 18% in Mar 2022, 82% in Mar 2024, and 20% in Mar 2025. Increased debt and inconsistent profits may strain financial stability.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings (₹ Cr) | 3,025 | 4,128 | 5,637 | 4,710 | 4,856 |
| Dividend Payout (%) | 0 | 18 | 0 | 82 | 20 |
Shareholding & Ownership Structure
Piramal Pharma's shareholding pattern shows some shifts. Promoter holding is stable around 34.78% to 35.02%. FII holding decreased from 39.28% in Mar 2023 to 31.49% in Mar 2025, while DII holding increased from 4.98% to 14.78%. Public holding decreased from 20.57% to 18.42%. The increasing DII stake and decreasing FII stake may reflect changing investor sentiment.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 34.78 | 35.02 | 34.94 |
| FII Holding (%) | 39.28 | 30.58 | 31.49 |
| DII Holding (%) | 4.98 | 12.12 | 14.78 |
Piramal Pharma's risk assessment reveals concerns including segment performance volatility and high tax rates. The increasing cash conversion cycle suggests potential inefficiencies in working capital management. Revenue growth has been positive, and promoter holding remains stable. The overall risk is assessed as Orange, suggesting a need for monitoring and strategic adjustments.
Segment performance volatility
Piramal Pharma shows segment performance volatility, with fluctuations in quarterly sales and operating profit margins. Quarterly sales vary from ₹1,482 Cr (Jun 2022) to ₹2,754 Cr (Mar 2025). OPM % fluctuates from 1% to 21%, demonstrating operational inconsistency. This variability may challenge stable performance across segments.
| Quarter | Sales (₹ Cr) | OPM (%) |
|---|---|---|
| Jun 2022 | 1,482 | 1 |
| Mar 2025 | 2,754 | 20 |
Accounting quality red flags
Piramal Pharma's tax rates show variation across quarters and years. The tax rate was 90% in Mar 2024 and 78% in Mar 2025. These high tax rates can significantly reduce net profit. Inconsistencies may warrant further scrutiny for accuracy.
| Year | Tax Rate (%) |
|---|---|
| Mar 2024 | 90 |
| Mar 2025 | 78 |
Foreign exchange or interest rate exposure
Piramal Pharma's interest expenses have increased from ₹163 Cr in Mar 2021 to ₹422 Cr in Mar 2025. This increase suggests a growing debt burden, potentially exposing the company to interest rate risk. Fluctuations in interest rates could impact profitability.
| Year | Interest Expense (₹ Cr) |
|---|---|
| Mar 2021 | 163 |
| Mar 2025 | 422 |
Regulatory compliance cost trends
Piramal Pharma's expenses have increased from ₹4,887 Cr in Mar 2021 to ₹7,706 Cr in Mar 2025. This increase could be due to rising regulatory compliance costs. Stricter regulations may require additional investments, impacting profitability.
| Year | Total Expenses (₹ Cr) |
|---|---|
| Mar 2021 | 4,887 |
| Mar 2025 | 7,706 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 10160.13Bearish
- SMA 20161.58Bearish
- SMA 50163.25Bearish
- EMA 10160.09Bearish
- EMA 20161.19Bearish
- EMA 50163.22Bearish
- DEMA 10158.92Bearish
- DEMA 20159.43Bearish
- DEMA 50160.49Bearish
- TEMA 10158.75Bullish
- TEMA 20158.89Bullish
- TEMA 50160.00Bearish
- MACD-1.36Bearish
- ADX17.38Weak Trend
- IndicatorValueSignal
- RSI33.39Neutral
- CCI-120.12Oversold
- ROC 9-1.31Bearish
- ROC 14-2.51Bearish
- ROC 25-2.41Bearish
- Stoch K8.01Oversold
- Stoch D8.15Oversold
- IndicatorValueSignal
- BB Upper165.12Neutral
- BB Middle161.58Neutral
- BB Lower158.05Neutral
- ATR1.41Low Volatility
- IndicatorValueSignal
- MFI15.80Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10160.98Bearish
- SMA 20163.09Bearish
- SMA 50165.05Bearish
- EMA 10160.77Bearish
- EMA 20162.16Bearish
- EMA 50164.89Bearish
- DEMA 10159.19Bearish
- DEMA 20159.99Bearish
- DEMA 50161.43Bearish
- TEMA 10158.78Bullish
- TEMA 20159.45Bearish
- TEMA 50159.52Bearish
- MACD-1.70Bearish
- ADX10.11Weak Trend
- IndicatorValueSignal
- RSI34.02Neutral
- CCI-131.18Oversold
- ROC 9-2.79Bearish
- ROC 14-1.83Bearish
- ROC 25-1.71Bearish
- Stoch K9.90Oversold
- Stoch D11.62Oversold
- IndicatorValueSignal
- BB Upper168.84Neutral
- BB Middle163.09Neutral
- BB Lower157.35Neutral
- ATR1.96Low Volatility
- IndicatorValueSignal
- MFI59.41Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10162.87Bearish
- SMA 20164.07Bearish
- SMA 50169.45Bearish
- EMA 10161.93Bearish
- EMA 20163.89Bearish
- EMA 50166.24Bearish
- DEMA 10159.88Bearish
- DEMA 20160.64Bearish
- DEMA 50166.92Bearish
- TEMA 10159.42Bearish
- TEMA 20159.73Bearish
- TEMA 50N/AN/A
- MACD-2.45Bearish
- ADX10.49Weak Trend
- IndicatorValueSignal
- RSI35.43Neutral
- CCI-152.28Oversold
- ROC 9-5.96Bearish
- ROC 14-3.10Bearish
- ROC 25-4.13Bearish
- Stoch K6.86Oversold
- Stoch D8.42Oversold
- IndicatorValueSignal
- BB Upper170.02Neutral
- BB Middle164.07Neutral
- BB Lower158.13Neutral
- ATR3.42Low Volatility
- IndicatorValueSignal
- MFI35.47Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10164.46Bearish
- SMA 20168.81Bearish
- SMA 50164.81Bearish
- SMA 100158.75Bullish
- SMA 200173.43Bearish
- EMA 10164.67Bearish
- EMA 20166.62Bearish
- EMA 50165.12Bearish
- EMA 100165.21Bearish
- EMA 200172.31Bearish
- DEMA 10161.86Bearish
- DEMA 20165.21Bearish
- DEMA 50168.15Bearish
- DEMA 100160.27Bearish
- DEMA 200159.00Bullish
- TEMA 10161.20Bearish
- TEMA 20161.42Bearish
- TEMA 50171.27Bearish
- TEMA 100166.30Bearish
- TEMA 200151.47Bullish
- MACD-1.50Bearish
- ADX19.23Weak Trend
- IndicatorValueSignal
- RSI40.74Neutral
- CCI-112.35Oversold
- ROC 14-7.29Bearish
- ROC 25-9.69Bearish
- Stoch K12.16Oversold
- Stoch D18.44Oversold
- IndicatorValueSignal
- BB Upper179.97Neutral
- BB Middle168.81Neutral
- BB Lower157.64Neutral
- ATR6.09Low Volatility
- IndicatorValueSignal
- MFI41.14Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20158.24Bullish
- SMA 50177.10Bearish
- EMA 20164.81Bearish
- EMA 50174.16Bearish
- DEMA 20161.31Bullish
- DEMA 50162.40Bullish
- TEMA 20167.58Bearish
- TEMA 50149.88Bullish
- MACD-1.49Bullish
- ADX25.88Strong Trend
- IndicatorValueSignal
- RSI46.74Neutral
- CCI-45.35Neutral
- ROC 147.89Bullish
- ROC 25-4.34Bearish
- Stoch K55.35Neutral
- Stoch D60.84Neutral
- IndicatorValueSignal
- BB Upper182.84Neutral
- BB Middle158.24Neutral
- BB Lower133.64Neutral
- ATR13.64Low Volatility
- IndicatorValueSignal
- MFI79.76Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6159.04Bullish
- SMA 12176.34Bearish
- SMA 24197.32Bearish
- EMA 6165.16Bullish
- EMA 12173.70Bearish
- EMA 24173.46Bearish
- DEMA 6158.32Bullish
- DEMA 12162.37Bullish
- DEMA 24N/AN/A
- TEMA 6162.16Bullish
- TEMA 12150.32Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX15.52Weak Trend
- IndicatorValueSignal
- RSI50.64Neutral
- CCIN/AN/A
- ROC 2520.29Bullish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper273.06Neutral
- BB Middle199.22Neutral
- BB Lower125.38Neutral
- ATR31.44High Volatility
- IndicatorValueSignal
- MFI44.46Neutral